Robert K. Weigle currently is and has been since April 1, 2023, the CEO of NOW Diagnostics. From October 2020 to March 2023, he was the CEO of AeenaDX, a saliva-based diagnostics company utilizing Genomics. Mr. Weigle is also currently an executive in residence with DigitalDX, a venture capital firm. Mr. Weigle was CEO and a director of Benvenue Medical from May 2009 until August 2020. Benvenue was a Silicon Valley based medical device company, which raised over $200 million in funding. At Benvenue Mr. Weigle led growth from pre-clinical to successful clinical trials to commercial launch of first-generation devices in two distinct markets, one for the treatment of compression fractures in the spine and the second for the treatment of degenerative disc disease, resulting in a first full year run rate exceeding $1 million per month. Mr. Weigle oversaw all early aspects of corporate strategy, including defining, communicating, and executing the company’s overall business model; and represented Benvenue to the investment community. Mr. Weigle was also a senior executive at numerous healthcare/medical device companies, including Johnson & Johnson, Baxter Healthcare, TherOx, Inc., (Zoll), Cardiac Pathways (Boston Scientific), and Camino Labs (Integra) Corp. Mr. Weigle was a member of the Board at Zyga (acquired by RTI) and currently is a Board member at Tenon, TNON NASDAQ. Mr. Weigle holds a BA from the University of California, Berkeley.